

## **Product datasheet for TL319537**

#### OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

### **GSC2** Human shRNA Plasmid Kit (Locus ID 2928)

#### **Product data:**

**Product Type:** shRNA Plasmids

**Product Name:** GSC2 Human shRNA Plasmid Kit (Locus ID 2928)

Locus ID: 2928 Synonyms: GSCL

Vector:pGFP-C-shLenti (TR30023)E. coli Selection:Chloramphenicol (34 ug/ml)

Mammalian Cell

**Cell** Puromycin

Selection:

Format: Lentiviral plasmids

Components: GSC2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 2928).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: <u>NM 005315, NM 005315.1, NM 005315.2</u>

UniProt ID: 015499

**Summary:** Goosecoidlike (GSCL), a homeodomain-containing gene, resides in the critical region for

VCFS/DGS on 22q11. Velocardiofacial syndrome (VCFS) is a developmental disorder

characterized by conotruncal heart defects, craniofacial anomalies, and learning disabilities.

VCFS is phenotypically related to DiGeorge syndrome (DGS) and both syndromes are associated with hemizygous 22q11 deletions. Because many of the tissues and structures affected in VCFS/DGS derive from the pharyngeal arches of the developing embryo, it is believed that haploinsufficiency of a gene involved in embryonic development may be responsible for its etiology. The gene is expressed in a limited number of adult tissues, as

well as in early human development. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).